Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies for Diabetes
Shots: Valneva to receive $308M in cash including $130M up front, $35M as development milestones and $143M as early commercialization milestones and will fund 30% of all development costs through completion of the development program while in exchange Pfizer will pay Valneva royalties starting at 19% Pfizer will lead the late stage development of VLA15 […]Read More
